8EQ Stock Chart & Stats
€3.92
€0.00(0.00%)
At close: 4:00 PM EDT
€3.92
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€2.82 - €5.60
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€652.49M
Enterprise Value€346.69
Total Cash (Recent Filing)€262.00M
Total Debt (Recent Filing)€26.46M
Price to Earnings (P/E)―
Beta0.55
Next Earnings
Nov 11, 2026EPS Estimate
-0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.62
Shares Outstanding129,983,250
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)1.89
Price to Sales (P/S)3.20
P/FCF Ratio-73.56
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€5.25Price Target Upside33.81% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.3
Revenue Forecast (FY)€180.70M
Bulls Say, Bears Say
Bulls Say
Recurring Revenue And Installed BaseA growing recurring revenue mix gives Cytek more predictable demand beyond one-time instrument sales. Reagent and service purchases should increase as the installed base expands, supporting customer retention, revenue visibility, and potentially more durable economics over the next several quarters.
Product InnovationNew instruments aimed at high-parameter and automated workflows can broaden Cytek’s addressable market and reinforce its technology differentiation. Strong early customer feedback, combined with expanded automation and API capabilities, supports future adoption across research and clinical applications.
Conservative Balance SheetVery low leverage limits interest and refinancing pressure while preserving capacity to fund product development, commercial expansion, and legal obligations. Although recent losses have reduced equity, the conservative capital structure gives Cytek more resilience than a highly indebted business.
Bears Say
Deteriorating ProfitabilityThe sharp move from prior profitability toward substantial net and operating losses indicates that revenue growth is not yet converting into earnings. Higher operating costs and weaker operating leverage could continue to constrain reinvestment, returns on capital, and the path to sustainable profitability.
Negative Cash GenerationNegative operating and free cash flow reduce internal funding capacity even with a conservatively levered balance sheet. If the burn persists, Cytek may need to use liquidity or seek external financing, limiting flexibility to invest in growth and absorb operating volatility.
Patent Litigation ExposureThe damages award creates a material financial and legal overhang that could absorb management attention and constrain capital allocation. Cytek plans post-verdict motions and potentially an appeal, but the unresolved outcome leaves exposure beyond normal operating risks.
8EQ FAQ
What was Cytek Biosciences’s price range in the past 12 months?
Cytek Biosciences lowest stock price was €2.82 and its highest was €5.60 in the past 12 months.
What is Cytek Biosciences’s market cap?
Cytek Biosciences’s market cap is €652.49M.
When is Cytek Biosciences’s upcoming earnings report date?
Cytek Biosciences’s upcoming earnings report date is Nov 11, 2026 which is in 48 days.
How were Cytek Biosciences’s earnings last quarter?
Cytek Biosciences released its earnings results on Aug 05, 2026. The company reported -€0.078 earnings per share for the quarter, beating the consensus estimate of -€0.081 by €0.003.
Is Cytek Biosciences overvalued?
According to Wall Street analysts Cytek Biosciences’s price is currently Undervalued.
Does Cytek Biosciences pay dividends?
Cytek Biosciences does not currently pay dividends.
What is Cytek Biosciences’s EPS estimate?
Cytek Biosciences’s EPS estimate is -0.06.
How many shares outstanding does Cytek Biosciences have?
Cytek Biosciences has 129,983,250 shares outstanding.
What happened to Cytek Biosciences’s price movement after its last earnings report?
Cytek Biosciences reported an EPS of -€0.078 in its last earnings report, beating expectations of -€0.081. Following the earnings report the stock price went down -1.072%.
Which hedge fund is a major shareholder of Cytek Biosciences?
Currently, no hedge funds are holding shares in DE:8EQ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cytek Biosciences Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€5.25 (33.81% Upside)
€5.25 (33.81% Upside)
Blogger Sentiment
Neutral
DE:8EQ Sentiment 50%
Sector Average 63%
Sector Average 63%
Technicals
SMA
Positive
20 days / 200 days
Momentum
53.09%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-9.40%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Cytek Biosciences
Cytek Biosciences, Inc. is a company dedicated to cell analysis solutions, offering advanced tools that facilitate scientific progress in both biomedical research and clinical settings. Their primary offerings include the Aurora and Northern Lights spectrum flow cytometers. These instruments conduct comprehensive cell analysis by leveraging fluorescence signatures from multiple lasers to differentiate between various fluorescent tags on individual cells. Complementing these, the Aurora Cell Sorter system utilizes full spectrum profiling technology to broaden the range of potential applications in cell analysis. Beyond instrumentation, Cytek provides essential reagents and kits. These include cFluor reagents, which are antibodies conjugated with fluorochromes, specifically designed to identify target cells for analysis on their systems. They also offer a 25-color immunoprofiling assay, a ready-to-use solution for pinpointing major human immune cell subpopulations like TBNK cells, monocytes, dendritic cells, and basophils. To streamline laboratory operations, the company offers automated micro-sampling and sample loader systems. These automated plate loaders are engineered to integrate seamlessly with the Aurora and Northern Lights systems. The intuitive SpectroFlo software accompanies these systems, simplifying the workflow from quality control through to data analysis. Cytek also provides comprehensive customer support resources. Cytek's diverse client base includes pharmaceutical and biopharmaceutical companies, academic research institutions, and clinical research organizations. The company distributes its products through a direct sales force and dedicated support teams in North America, Europe, China, and the Asia-Pacific region. Additionally, it partners with distributors and sales agents to serve markets across European, Latin American, Middle Eastern, and other Asia-Pacific countries. Originally established in 1992 as Cytoville, Inc., the company officially adopted the name Cytek Biosciences, Inc. in August 2015. Its corporate headquarters are situated in Fremont, California.
8EQ Company Deck
8EQ Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presents a mixed but cautiously constructive picture: revenue growth (6% YoY) driven by strong performance in the U.S. and China, expansion of installed base, growing recurring revenue (35% of LTM), and strategic product launches (Borealis and Aurora Evo) underpin future upside. Offsetting these positives are widening GAAP losses, a Q2 adjusted EBITDA decline, regional weaknesses in EMEA and parts of APAC, rising operating expenses (including litigation-related G&A increases), and some one-time items (tariff refund, investment write-off) that cloud margin comparability. Management raised the low end of guidance and expects H2 improvement, but several challenges (regional budgetary pressures, delayed clinical penetration in the U.S., and reorganization timeline) temper near-term outlook.View all DE:8EQ earnings summaries8EQ Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
€5.25
▲(33.81% Upside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month










